ArticleESMO open2026
Genomic and transcriptomic evaluation of primary and recurrent luminal B-like breast cancer.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLuminal B-like breast cancer (LBBC) constitutes approximately 40% of breast cancer cases and carries a higher risk of recurrence and poorer prognosis than luminal A-like disease. This study aimed to investigate the molecular alterations between primary and recurrent LBBC tumors, elucidate the drivers of LBBC recurrence and identify potential therapeutic targets. MATERIALS AND
methodsWe performed DNA sequencing using a custom-designed panel covering 769 cancer-related genes and RNA sequencing (RNA-seq) on 15 LBBC patients (49 samples: 15 primary tumors, 21 recurrent lesions and 15 blood samples; six patients had two recurrent lesions each). Of these, 13 had paired-end DNA sequencing data and five had paired-end RNA-seq data (three of whom also had DNA data). Molecular features altered in recurrent tumors were compared with their corresponding primary tumors, focusing on gene mutations, copy number alterations, tumor heterogeneity, gene expression, pathways, and immune cell composition. Molecular features associated with LBBC recurrence were further identified.
resultsThe majority of gene mutations and copy number alterations are primarily established in the primary tumor and persist through recurrence. TP53 and PIK3CA were the most frequently altered genes in both primary and recurrent tumors, whereas mutations in EGFR and GNAS emerged in recurrent tumors. Upregulated pathways in recurrences included cell cycle checkpoints, DNA replication, and antigen processing-cross-presentation. Compared with primary tumors, recurrent tumors exhibited an increased abundance of T cells in the tumor microenvironment. Furthermore, higher mutant-allele tumor heterogeneity (MATH) scores in primary tumors were associated with worse recurrence-free survival in exploratory unadjusted analysis (P = 0.032).
conclusionsOur study reveals the genomic and transcriptomic evolution of LBBC recurrence, suggesting that most drivers are established in the primary tumor. Acquired mutations or alterations warrant further investigation as potential therapeutic targets and MATH scores may represent a candidate biomarker associated with LBBC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.